{"doc_id": "33332778", "type of study": "Therapy", "title": "", "abstract": "REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.\nRecent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads.\nIn this ongoing, double-blind, phase 1-3 trial involving nonhospitalized patients with Covid-19, we investigated two fully human, neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, used in a combined cocktail (REGN-COV2) to reduce the risk of the emergence of treatment-resistant mutant virus.\nPatients were randomly assigned (1:1:1) to receive placebo, 2.4 g of REGN-COV2, or 8.0 g of REGN-COV2 and were prospectively characterized at baseline for endogenous immune response against SARS-CoV-2 (serum antibody-positive or serum antibody-negative).\nKey end points included the time-weighted average change in viral load from baseline (day 1) through day 7 and the percentage of patients with at least one Covid-19-related medically attended visit through day 29.\nSafety was assessed in all patients.\nData from 275 patients are reported.\nThe least-squares mean difference (combined REGN-COV2 dose groups vs. placebo group) in the time-weighted average change in viral load from day 1 through day 7 was -0.56 log10 copies per milliliter (95% confidence interval [CI], -1.02 to -0.11) among patients who were serum antibody-negative at baseline and -0.41 log10 copies per milliliter (95% CI, -0.71 to -0.10) in the overall trial population.\nIn the overall trial population, 6% of the patients in the placebo group and 3% of the patients in the combined REGN-COV2 dose groups reported at least one medically attended visit; among patients who were serum antibody-negative at baseline, the corresponding percentages were 15% and 6% (difference, -9 percentage points; 95% CI, -29 to 11).\nThe percentages of patients with hypersensitivity reactions, infusion-related reactions, and other adverse events were similar in the combined REGN-COV2 dose groups and the placebo group.\nIn this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline.\nSafety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group. (Funded by Regeneron Pharmaceuticals and the Biomedical and Advanced Research and Development Authority of the Department of Health and Human Services; ClinicalTrials.gov number, NCT04425629.).\nCopyright \u00a9 2020 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "Outpatients", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 61}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 97}, {"term": "serum antibody-negative", "negation": "affirmed", "UMLS": {}, "start": 278, "end": 301}, {"term": "serum antibody-negative", "negation": "affirmed", "UMLS": {}, "start": 210, "end": 233}, {"term": "immune response", "negation": "affirmed", "UMLS": {}, "start": 120, "end": 135}, {"term": "high viral load", "negation": "affirmed", "UMLS": {}, "start": 176, "end": 191}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "REGN-COV2 , a Neutralizing Antibody Cocktail , in Outpatients with Covid-19 .", "Evidence Elements": {"Participant": [{"term": "Outpatients", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 61}], "Intervention": [{"term": "REGN-COV2", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 9, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Recent data suggest that complications and death from coronavirus disease 2019 ( Covid-19 ) may be related to high viral loads .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In this ongoing , double-blind , phase 1-3 trial involving nonhospitalized patients with Covid-19 , we investigated two fully human , neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) spike protein , used in a combined cocktail ( REGN-COV2 ) to reduce the risk of the emergence of treatment-resistant mutant virus .", "Evidence Elements": {"Participant": [{"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 97}], "Intervention": [], "Outcome": [{"term": "acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) spike protein", "negation": "affirmed", "UMLS": {}, "start": 184, "end": 253}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomly assigned ( 1:1:1) to receive placebo , 2.4 g of REGN-COV2 , or 8.0 g of REGN-COV2 and were prospectively characterized at baseline for endogenous immune response against SARS-CoV-2 ( serum antibody-positive or serum antibody-negative ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 59, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "2.4 g of REGN-COV2", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 80, "has_relation": "N/A"}, {"term": "8.0 g of REGN-COV2", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 104, "has_relation": "N/A"}], "Outcome": [{"term": "endogenous immune response against SARS-CoV-2", "negation": "affirmed", "UMLS": {}, "start": 158, "end": 203}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Key end points included the time-weighted average change in viral load from baseline ( day 1 ) through day 7 and the percentage of patients with at least one Covid-19-related medically attended visit through day 29 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "time-weighted average change in viral load", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 70}, {"term": "baseline", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 84}, {"term": "percentage of patients with at least one Covid-19-related medically attended visit", "negation": "affirmed", "UMLS": {}, "start": 117, "end": 199}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Safety was assessed in all patients .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Data from 275 patients are reported .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The least-squares mean difference ( combined REGN-COV2 dose groups vs . placebo group ) in the time-weighted average change in viral load from day 1 through day 7 was -0.56 log10 copies per milliliter ( 95 % confidence interval [ CI ] , -1.02 to -0.11 ) among patients who were serum antibody-negative at baseline and -0.41 log10 copies per milliliter ( 95 % CI , -0.71 to -0.10 ) in the overall trial population .", "Evidence Elements": {"Participant": [{"term": "serum antibody-negative", "negation": "affirmed", "UMLS": {}, "start": 278, "end": 301}], "Intervention": [{"term": "combined REGN-COV2 dose", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 59, "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 79, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "least-squares mean difference", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 33}, {"term": "time-weighted average change in viral load", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 137}], "Observation": [{"term": "-0.56 log10 copies per milliliter", "negation": "affirmed", "UMLS": {}, "start": 167, "end": 200}, {"term": "-0.41 log10 copies per milliliter", "negation": "affirmed", "UMLS": {}, "start": 318, "end": 351}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "combined REGN-COV2 dose", "has_relation": "N/A"}, "Observation": "-0.56 log10 copies per milliliter", "Outcome": "least-squares mean difference", "Count": ""}, {"Intervention": {"term": "combined REGN-COV2 dose", "has_relation": "N/A"}, "Observation": "-0.56 log10 copies per milliliter", "Outcome": "time-weighted average change in viral load", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "-0.56 log10 copies per milliliter", "Outcome": "least-squares mean difference", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "-0.56 log10 copies per milliliter", "Outcome": "time-weighted average change in viral load", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "-0.41 log10 copies per milliliter", "Outcome": "time-weighted average change in viral load", "Count": ""}]}, {"Section": "RESULTS", "Text": "In the overall trial population , 6 % of the patients in the placebo group and 3 % of the patients in the combined REGN-COV2 dose groups reported at least one medically attended visit ; among patients who were serum antibody-negative at baseline , the corresponding percentages were 15 % and 6 % ( difference , -9 percentage points ; 95 % CI , -29 to 11 ) .", "Evidence Elements": {"Participant": [{"term": "serum antibody-negative", "negation": "affirmed", "UMLS": {}, "start": 210, "end": 233}], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 68, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "combined REGN-COV2 dose", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 129, "has_relation": "N/A"}], "Outcome": [{"term": "one", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 158}, {"term": "medically attended visit", "negation": "affirmed", "UMLS": {}, "start": 159, "end": 183}, {"term": "corresponding percentages", "negation": "affirmed", "UMLS": {}, "start": 252, "end": 277}], "Observation": [{"term": "15 %", "negation": "affirmed", "UMLS": {}, "start": 283, "end": 287}, {"term": "6 %", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 37}], "Count": [{"term": "6 % of the patients", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 53}, {"term": "3 % of the patients", "negation": "affirmed", "UMLS": {}, "start": 79, "end": 98}]}, "Evidence Propositions": [{"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "15 %", "Outcome": "corresponding percentages", "Count": ""}]}, {"Section": "RESULTS", "Text": "The percentages of patients with hypersensitivity reactions , infusion-related reactions , and other adverse events were similar in the combined REGN-COV2 dose groups and the placebo group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combined REGN-COV2 dose", "negation": "affirmed", "UMLS": {}, "start": 136, "end": 159, "has_relation": "N/A"}], "Outcome": [{"term": "percentages of patients with hypersensitivity reactions , infusion-related reactions", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 88}, {"term": "and other adverse events", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 115}], "Observation": [{"term": "similar", "negation": "affirmed", "UMLS": {}, "start": 121, "end": 128}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "combined REGN-COV2 dose", "has_relation": "N/A"}], "Observation": "similar", "Outcome": "percentages of patients with hypersensitivity reactions , infusion-related reactions", "Count": ""}, {"Intervention": [{"term": "combined REGN-COV2 dose", "has_relation": "N/A"}], "Observation": "similar", "Outcome": "and other adverse events", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "In this interim analysis , the REGN-COV2 antibody cocktail reduced viral load , with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline .", "Evidence Elements": {"Participant": [{"term": "immune response", "negation": "affirmed", "UMLS": {}, "start": 120, "end": 135}, {"term": "high viral load", "negation": "affirmed", "UMLS": {}, "start": 176, "end": 191}], "Intervention": [{"term": "REGN-COV2 antibody cocktail", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 58, "has_chemical": [{"text": "regn cov2 antibody", "maps_to": "C0003241:antibody", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [{"term": "viral load", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 77}], "Observation": [{"term": "reduced", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 66}, {"term": "greater effect", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 101}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group . ( Funded by Regeneron Pharmaceuticals and the Biomedical and Advanced Research and Development Authority of the Department of Health and Human Services ; ClinicalTrials.gov number , NCT04425629 . ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combined REGN-COV2 dose", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 59, "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 82, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "Safety outcomes", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 15}], "Observation": [{"term": "similar", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 28}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "combined REGN-COV2 dose", "has_relation": "N/A"}, {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Observation": "similar", "Outcome": "Safety outcomes", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}